Preclinical assessment of inhalational subacute safety of nebulized MP-171 (BromAc®)
Abstract BromAc® (MP-171) is a novel first in class therapeutic agent under investigation for its potential in treating respiratory diseases. Evaluating its safety profile following inhalation is necessary for future clinical application. Here, we evaluated BromAc® safety in an extended subacute sho...
Uloženo v:
| Hlavní autoři: | , , , , , , , |
|---|---|
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
BMC
2026-01-01
|
| Edice: | BMC Pulmonary Medicine |
| Témata: | |
| On-line přístup: | https://doi.org/10.1186/s12890-025-04090-1 |
| Tagy: |
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|